Skip to content

Low Intraocular Pressure Cataract Surgery With Zeiss Quatera in Glaucoma Patients

Low Intraocular Pressure Cataract Surgery With Zeiss Quatera in Glaucoma Patients. Prospective, Investigator Initiated and Observational Case Series

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06712758
Enrollment
10
Registered
2024-12-02
Start date
2024-11-12
Completion date
2025-12-31
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Glaucoma

Keywords

intra ocular pressure, cataract, Quatera, glaucoma

Brief summary

You were selected to participate in this observational study because you suffer from glaucoma and cataracts. For the cataract you will have cataract surgery. This study will not affect your treatment, it will only collect data on what is performed before, during and after the procedure. The aim of this data collection is to demonstrate the safety of a new generation of cataract surgical devices in patients who also suffer from glaucoma. They are glaucoma patients who have an increased sensitivity to eye pressure increases both during and after surgery. The new surgical device makes it possible to safely perform cataract surgery under low pressures. This could, at least theoretically, provide an advantage for patients who also suffer from glaucoma.

Detailed description

Cataract surgery is a highly standardized procedure. However a new phacoemulsification system Quatera 700 has been developed by Carl Zeiss Meditec. The system has a unique patented QUATTRO Pump that directly controls infusion and aspiration and enables a synchronous change in both. It has four membranes, which directly regulate infusion and aspiration and maintain a pre-set intraocular pressure (IOP), resulting in a stable anterior chamber during the surgery. The membranes are activated by pneumatic pressure regulated by sensors that measure infusion and aspiration flows which allows the system to determine and compensate for incisional leakage as well. This innovative pump system allows surgeons to significantly decrease the intra-ocular pressure during cataract surgery. In respect to competitive devices on the market, the Quatera system is able to operate with pressure four times lower than average. Especially in glaucoma patients (patients suffering from optic nerve head damage due to elevated intraocular pressures), performing surgery with lower intra-ocular pressures would help in avoiding extra nerve fiber layer damage and overall safety of the surgery.

Interventions

None listed

Sponsors

Visionair Oogzorg
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with glaucoma that are diagnosed with age-related cataract

Exclusion criteria

* Unwilling to sign informed consent * Functionally monophtalmic patient * Endothelial dystrophy * Active uveitis * Known corticosteroid responder * Presence of uncontrolled systemic disease

Design outcomes

Primary

MeasureTime frameDescription
Complication rate during cataract surgeryMonth 1Complication rate during cataract surgery

Secondary

MeasureTime frameDescription
Best corrected visual acuityMonth 1Best corrected visual acuity will be determined and recorded at the preoperative, day 1, week 1 and month 1 visit.
Intraocular pressure1 monthThe intraocular pressure will be measured at the preoperative, day 1, week 1 and month 1 visit. Ocular hypertension will reported.
Retinal nerve fiber layer thickness1 yearOptical Coherence Tomography will be performed at the preoperative and month 1 visit. Any abnormalities will be described.
Visual field mean deviationMonth 1The visual field examination will be performed at the preoperative and month 1 visit. Any abnormalities will be described.

Countries

Belgium

Contacts

Primary ContactKoen Willekens, Prof
kw@visionairoogzorg.be003214808311
Backup ContactSien Boons
sb@visionairoogzorg.be003216715634

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026